Navigation Links
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Date:11/5/2009

, completion of all AGW trial activities in accordance with the trial design and schedule. Important risk factors and uncertainties that could cause actual results to differ materially from these forward-looking statements and information include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse impact on the Company and its ability to continue, or if not obtained in a timely manner, may result in the Company's having to discontinue or delay one or more of its product development programs, including the AGW trial; uncertainty whether Topical Interferon Alpha-2b will be successfully developed and commercialized as a drug for the treatment of AGW or at all; uncertainty whether any of the timelines mentioned in this press release will be achieved; Helix's dependence on its third party service providers, including without limitation, contract research organizations, contract manufacturing organizations, clinical trial consultants, collaborative research consultants, regulatory affairs advisors, and others, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; the risk that the AGW trial may fail to meet expectations and that further development of the drug candidate may be discontinued for the AGW indication; the need for additional clinical trials, if the AGW trial does meet expectations, to continue the development of the drug candidate, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, including the possibility that further challenges may arise in connection with the scale-up manufacturing of Topical Interferon Alpha-2b; the risk of obtaining negative findings or factors that may become apparent during the course of research or development, including during the course of the AGW trial, w
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioPharma Corp. Announces Fiscal 2009 Results
2. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
3. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
4. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
5. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
6. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... 2014  Sage Analytics ( www.sageanalytics.com ), the ... the testing of marijuana potency and moisture content, ... Profiler, the industry,s first product suite capable of ... portable unit. Designed from the ground ... cannabis industry, the Luminary™ Profiler utilizes specially purposed ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... NEW YORK, Oct. 25, 2011 ... research report is available in its ... Disease Market to 2017 - Patent ... as Aricept, Namenda, Avonex, Rebif and ...
... Leading events organiser UBM Live , a division ... a new event, CPhI South East Asia to cater to ... 10 to 12 May at the Jakarta International Expo in ... pharmaceutical events is being introduced to offer a meeting place ...
Cached Medicine Technology:Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15CPhI Global Portfolio Expands into South East Asia 2
(Date:12/22/2014)... (PRWEB) December 22, 2014 Coral Gables is ... service , Lice Troopers, with its new clinic location set ... Florida, takes the hassle out of dealing with this common ... one of their two salon clinic locations in South Florida, ... location. , The decision to expand developed naturally out of ...
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... Super Saturday, the last Saturday before Christmas, is ... day in the 2014 holiday shopping season. , ... steady pre-Christmas stream of customers, ready to purchase marijuana ... definitely intend to take advantage…of the recreational cannabis as ... enjoying The Grass Station’s holiday sale on vape products. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... Dallas, Texas (PRWEB) December 22, 2014 Luxury ... with Community Partners of Dallas to provide logistics ... A Dallas-based company, Peacock Alley has a long history of ... works. The additional sponsors of this year's Toy Drive were ... time to give back than the holidays. Providing gifts to ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... 03, 2007 - Gastroesophageal reflux disease (GERD), often known ... been associated with cancers, asthma, recurrent aspiration and pulmonary ... of Gastroenterology examines whether GERD sufferers may have shorter ... on over 50,000 person-years of data, the study provides ...
... CAMBRIDGE, Mass., Jan. 3, 2008 -- Psychologists at Harvard ... perception that, they argue, can resolve the century-old debate ... not only illustrates a new method for studying such ... against the existence of extrasensory perception, or ESP. , ...
... 23 million Americans age 12 or older need treatment for ... than 10 percent actually receive it. Worse, among those ... treatments that are known to work. , We have treatments ... Paul Roman, University of Georgia Distinguished Research Professor of Sociology ...
... VICTORIA, Jan. 3 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... completion of the,plan of arrangement with Galenica Group ... Canadian subsidiary, acquired all,outstanding shares of Aspreva for ... completion of the plan of arrangement, Aspreva will ...
... Jan. 3 DaVita Inc. (NYSE:,DVA) announced today that ... January 7-11, 2008 at the Westin St. Francis Hotel ... will be presenting on,January 8, at 9:00 a.m. Pacific ... presentation will also be broadcast live and by replay. ...
... The Jeffrey Modell Foundation drives initiative for SCID screening, ... became the first,state in the nation to screen all ... "Bubble Boy Disease," SCID is a,genetic disorder that is ... referred for potentially life-saving treatment., The Wisconsin Department ...
Cached Medicine News:Health News:Researchers use neuroimaging to study ESP 2Health News:Researchers use neuroimaging to study ESP 3Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 2Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 3Health News:Aspreva's plan of arrangement with Galenica completed 2Health News:Aspreva's plan of arrangement with Galenica completed 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 2Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 4Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: